Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
C-Max (Cerebrolysin variant) vs Zilucoplan (Zilbrysq)
An educational, source-based comparison of C-Max (Cerebrolysin variant) and Zilucoplan (Zilbrysq) — how each peptide works, what it's researched for, and what to know before going deeper.
Concentrated neuropeptide fraction for cognitive support research.
A concentrated fraction of cerebrolysin containing specific neuropeptide sequences. Research suggests enhanced delivery of neurotrophic factors supporting synaptic maintenance and neurogenesis.
- Post-stroke cognitive recovery
- Vascular cognitive impairment
- Traumatic brain injury rehabilitation
- • Not FDA-approved in the US; approved in select countries.
- • Requires medical supervision for IV administration.
Macrocyclic peptide complement C5 inhibitor for generalized myasthenia gravis.
A synthetic 15-amino-acid macrocyclic peptide that binds complement component C5 and blocks its cleavage to C5a/C5b, preventing formation of the membrane attack complex at the neuromuscular junction. Self-administered subcutaneously.
- Generalized myasthenia gravis (anti-AChR antibody positive)
- • FDA-approved 2023.
- • Requires meningococcal vaccination — risk of serious meningococcal infection.
- • Injection-site reactions common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| C-Max (Cerebrolysin variant) | Concentrated neuropeptide fractions in stroke rehabilitation | Neurorehabilitation and Neural Repair | 2018 | Improved functional outcomes in post-stroke patients receiving neuropeptide therapy. |
| Zilucoplan (Zilbrysq) | RAISE phase 3 trial of zilucoplan in gMG | Lancet Neurology | 2023 | Significant improvement in MG-ADL and QMG scores vs placebo at week 12. |
Side-effect & safety grid
- Not FDA-approved in the US; approved in select countries.
- Requires medical supervision for IV administration.
- FDA-approved 2023.
- Requires meningococcal vaccination — risk of serious meningococcal infection.
- Injection-site reactions common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
C-Max (Cerebrolysin variant) vs Zilucoplan (Zilbrysq) — Key differences
- Class: C-Max (Cerebrolysin variant) is classified as Nootropic · Neurotrophic, while Zilucoplan (Zilbrysq) is Complement Inhibitor · Neuromuscular.
- Primary research focus: C-Max (Cerebrolysin variant) — post-stroke cognitive recovery; Zilucoplan (Zilbrysq) — generalized myasthenia gravis (anti-achr antibody positive).
- Tag: Cognition vs FDA-Approved · Neuromuscular.